Resumen

RIBEIRO, Sandra; SANTOS, Joaquim; FROIS, Ana Teresa  y  MENDES, Joana. Vortioxetine in mild cognitive impairment: literature review. Psic., Saúde & Doenças [online]. 2023, vol.24, n.2, pp.491-497.  Epub 31-Oct-2023. ISSN 1645-0086.  https://doi.org/10.15309/23psd240206.

Mild cognitive impairment is a stage between the cognitive alterations and an initial stage of dementia. Pharmacologic treatments for this condition are scarce and their efficacy is still under assessment. This review aims at gathering existing scientific evidence regarding the benefits of vortioxetine in mild cognitive impairment. The research included metanalyses, systematic reviews, clinical trials, observational studies, and guidelines indexed in MEDLINE/Pubmed, The Cochrane Library, Database of Abstracts of Reviews of Effects (DARE), National Guideline Clearinghouse, BMJ Evidence-Based Medicine (BMJ EBM), National Institute for Health and Care Excellence (NICE), Canadian Medical Association Practice Guidelines Infobase, and Bandolier, using MeSH terms “Vortioxetine” and “Cognitive Dysfunction”. Publications from any linguistic background were considered, with no language restrictions. The evidence level and recommendation strength were defined using the American Academy of Family Physicians’ Strength of Recommendation Taxonomy (SORT). In the original research, 127 articles were found, of which 125 were excluded for not meeting inclusion criteria or for meeting exclusion criteria. In the end, two studies were included in the revision. Both studies showed that vortioxetine appeared more effective than placebo in obtaining an improvement of cognitive function in individuals with mild cognitive impairment, thus it may be beneficial in those without contraindications to its use (Strength of Recommendation B). However, further studies are needed to prove this benefit.

Palabras clave : Cognitive Dysfunction; Vortioxetine; Review.

        · resumen en Portugués     · texto en Portugués     · Portugués ( pdf )